hepatitis B

Hepatitis B drug developers chart slow progress forward, just like hep C before it
Hepatitis B drug developers chart slow progress forward, just like hep C before it
Fierce Biotech
hepatitis B
hepatitis C
drug development
Assembly Biosciences
GSK
Aligos Therapeutics
Flag link:
Vaccitech reemerges as Barinthus with hep B data showing declines in infection levels
Vaccitech reemerges as Barinthus with hep B data showing declines in infection levels
Fierce Biotech
Barinthus Biotherapeutics
Vaccitech
clinical trials
hepatitis B
Flag link:
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
GSK
JNJ
hepatitis B
JNJ-3989
Janssen
Flag link:
Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group
Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group
Fierce Biotech
Gilead Sciences
Assembly Biosciences
antivirals
hepatitis B
Flag link:
Aligos culls another hepatitis B asset, citing inconclusive efficacy data
Aligos culls another hepatitis B asset, citing inconclusive efficacy data
Fierce Biotech
Algios Therapeutics
hepatitis B
siRNA
Flag link:
Gilead reports positive results in HDV patients previously unresponsive to therapy
Gilead reports positive results in HDV patients previously unresponsive to therapy
Motley Fool
Gilead Sciences
MYR301
Hepcludex
hepatitis B
clinical trials
Flag link:
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Clinical Trials Arena
Bluejay Therapeutics
clinical trials
BJT-778
hepatitis B
hepatitis D
Flag link:
Vaccitech’s chronic Hepatitis B drug sees positive topline data
Vaccitech’s chronic Hepatitis B drug sees positive topline data
Clinical Trials Arena
Vaccitech
VTP-300
clinical trials
hepatitis B
Flag link:
GSK moves hepatitis B drug into late-stage testing
GSK moves hepatitis B drug into late-stage testing
BioPharma Dive
GSK
bepirovirsen
clinical trials
hepatitis B
Flag link:
Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs
Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs
Endpoints
Assembly Biosciences
John McHutchison
hepatitis B
ABI-H3733
Flag link:
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop
GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop
Pharmaphorum
GSK
hepatitis B
bepirovirsen
clinical trials
Flag link:
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
BioSpace
Roche
hepatitis B
geographic atrophy
Flag link:
Bluejay raises $41M to bring hepatitis B drugs to clinical testing
Bluejay raises $41M to bring hepatitis B drugs to clinical testing
BioPharma Dive
Bluejay Therapeutics
hepatitis B
funding
Flag link:
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
Hepatitis B: can GSK’s bepirovirsen deliver functional cure?
Clinical Trials Arena
GSK
bepirovirsen
hepatitis B
antisense
Flag link:
Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback
Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback
BioPharma Dive
Assembly Biosciences
hepatitis B
layoffs
vebicorvir
Flag link:
GSK hepatitis B hope bepirovirsen heads for phase 3 test
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Pharmaforum
GSK
hepatitis B
clinical trials
antisense
bepirovirsen
Flag link:
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
Fierce Biotech
Antios
hepatitis B
Assembly Biosciences
FDA
Flag link:
J&J ends hepatitis B and HPV portions of Bavarian Nordic collab
J&J ends hepatitis B and HPV portions of Bavarian Nordic collab
Endpoints
JNJ
Janssen
Bavarian Nordic
vaccines
hepatitis B
HPV
Flag link:
Xbiome acquires live biotherapeutic product program targeting ulcerative colitis
Xbiome acquires live biotherapeutic product program targeting ulcerative colitis
Biopharma Reporter
Xbiome
microbiome
hepatitis B
artificial intelligence
ulcerative colitis
Flag link:
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism
Fierce Biotech
Finch Therapeutics
hepatitis B
microbiome
clinical trials
autism
C. difficile
Flag link:

Pages